Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1395 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Alexandre Duong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Montréal, QC, Canada. Hauptthemen laut MEDLINE: Tobramycin, Bayes Theorem, Gentamicins, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The objective of this project is to compare the results of the same study carried out on NONMEM and nlmixr2. This analysis consists of evaluating previously published population pharmacokinetic models of gentamicin and tobramycin in our population of interest with sparse concentrations. A literature review was performed to determine the gentamicin and tobramycin models in critically ill adult patients. In parallel, gentamicin and tobramycin dosing data, information on the treatment, the patient, and the bacteria were collected retrospectively in 2 Quebec establishments. The external evaluations were previously performed using NONMEM Version 7.5. Model equations were rewritten with R, and external evaluations were performed using nlmixr2. Predictive performance was assessed based on the estimation of bias and imprecision of the prediction error for maximum a posteriori (MAP) Bayesian PK parameter and observed concentrations. Comparison between nlmixr2 and NONMEM was performed on 4 gentamicin and 3 tobramycin population pharmacokinetic models. Compared to NONMEM, for gentamicin and tobramycin clearance and central volume of distribution, nlmixr2 produced individual pharmacokinetic parameters with bias values ranging from −32.5% to 5.67% and imprecision values ranging from 6.33% to 32.5%. Despite these differences, population bias and imprecision for sparse concentrations were low and ranged from 0% to 5.3% and 0.2% to 6.5%, respectively. The external evaluations performed with both software packages resulted in the same interpretation in terms of population predictive performance for all 7 models. Nlmxir2 showed comparable predictive performance with NONMEM with sparse concentrations that are, at most, sampled twice within a single dose administration (peak and trough).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Montréal, QC, Canada.
- Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada.
- Centre de Recherche CHU Sainte-Justine, Montréal, QC, Canada.
Zitieren
APA
Duong, A., & Marsot, A. (2024). Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1395
Vancouver
Duong A, Marsot A. Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1395
BibTeX
@article{Duong2024,
author = {Duong, Alexandre and Marsot, Amélie},
title = {Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1395}
}
EUVIMED